{"id":58563,"date":"2026-03-02T14:16:49","date_gmt":"2026-03-02T06:16:49","guid":{"rendered":"https:\/\/flcube.com\/?p=58563"},"modified":"2026-03-02T14:16:49","modified_gmt":"2026-03-02T06:16:49","slug":"healzens-btk-inhibitor-hz-a-018-wins-nmpa-approval-for-csu-phase-ii-expands-autoimmune-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58563","title":{"rendered":"HealZen&#8217;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline"},"content":{"rendered":"\n<p><strong>Hangzhou HealZen Therapeutics Co., Ltd.<\/strong> announced that its <strong>self\u2011developed Category\u202f1 innovative drug<\/strong>, <strong>HZ\u2011A\u2011018 capsules<\/strong>, has received <strong>clinical approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to conduct a <strong>Phase II trial<\/strong> for the <strong>monotherapy of chronic spontaneous urticaria (CSU)<\/strong>. The <strong>highly selective BTK inhibitor<\/strong> adds a <strong>dermatologic autoimmune indication<\/strong> to its expanding pipeline spanning <strong>oncology and multiple immunology targets<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hangzhou HealZen Therapeutics Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HZ\u2011A\u2011018 capsules<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 innovative drug; highly selective small\u2011molecule BTK inhibitor<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Irreversible binding to BTK active site \u2192 inhibits downstream signal transduction<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA clinical approval for Phase II<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Chronic spontaneous urticaria (CSU) \u2013 monotherapy<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase II initiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-indications\">Pipeline Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Status<\/th><th>Indication<\/th><th>Category<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase II (Newly Approved)<\/strong><\/td><td>Chronic spontaneous urticaria (CSU)<\/td><td>Autoimmune\/Dermatology<\/td><\/tr><tr><td><strong>Approved for Clinical Trials<\/strong><\/td><td>B\u2011cell lymphoma<\/td><td>Oncology<\/td><\/tr><tr><td><strong>Approved for Clinical Trials<\/strong><\/td><td>Chronic\/persistent primary immune thrombocytopenia (ITP)<\/td><td>Autoimmune\/Hematology<\/td><\/tr><tr><td><strong>Approved for Clinical Trials<\/strong><\/td><td>Multiple sclerosis (MS)<\/td><td>Autoimmune\/Neurology<\/td><\/tr><tr><td><strong>Approved for Clinical Trials<\/strong><\/td><td>Neuromyelitis optica spectrum disorders (NMOSD)<\/td><td>Autoimmune\/Neurology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BTK Platform Validation:<\/strong> <strong>Multiple approved indications<\/strong> (lymphoma, ITP, MS, NMOSD, CSU) demonstrate <strong>broad applicability<\/strong> of HealZen&#8217;s <strong>selective BTK inhibitor platform<\/strong>, supporting <strong>pipeline optionality<\/strong> and <strong>partnership attractiveness<\/strong>.<\/li>\n\n\n\n<li><strong>CSU Market Opportunity:<\/strong> Chronic spontaneous urticaria affects <strong>millions globally<\/strong> with limited effective options beyond antihistamines and omalizumab; <strong>BTK inhibition<\/strong> offers a <strong>novel mechanism<\/strong> targeting mast cell and B\u2011cell activation pathways.<\/li>\n\n\n\n<li><strong>Autoimmune Differentiation:<\/strong> Unlike first\u2011generation BTK inhibitors (ibrutinib) with cardiovascular and bleeding risks, <strong>HZ\u2011A\u2011018&#8217;s selectivity profile<\/strong> may enable <strong>safer chronic administration<\/strong> in autoimmune populations.<\/li>\n\n\n\n<li><strong>China\u2011First Development:<\/strong> <strong>NMPA approvals across five indications<\/strong> position HealZen for <strong>domestic leadership<\/strong> with potential <strong>global out\u2011licensing<\/strong> opportunities as clinical data matures.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>CSU Market Size<\/strong><\/td><td>~\u202f$2\u20113\u202fbillion globally; high unmet need for refractory patients failing H1 antihistamines<\/td><\/tr><tr><td><strong>BTK Inhibitor Evolution<\/strong><\/td><td>Shift from oncology (B\u2011cell lymphoma) to autoimmune (RA, MS, ITP, urticaria); selective inhibitors preferred for chronic use<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Evobrutinib (Merck), fenebrutinib (Roche) in Phase III for MS; remibrutinib (Novartis) in CSU Phase III\u2014HZ\u2011A\u2011018&#8217;s selectivity profile may differentiate<\/td><\/tr><tr><td><strong>HealZen Positioning<\/strong><\/td><td>Multi\u2011indication BTK platform rare among Chinese biotechs; supports Series B\/C financing and M&amp;A interest<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II enrollment, efficacy outcomes across indications, and partnership potential for HZ\u2011A\u2011018. Actual results may differ due to risks including competitive BTK inhibitor development, autoimmune safety signals, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2899],"class_list":["post-58563","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-healzen-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HealZen&#039;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has received clinical approval from China&#039;s National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58563\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HealZen&#039;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline\" \/>\n<meta property=\"og:description\" content=\"Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has received clinical approval from China&#039;s National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58563\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T06:16:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58563#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58563\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HealZen&#8217;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline\",\"datePublished\":\"2026-03-02T06:16:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58563\"},\"wordCount\":427,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HealZen Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58563#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58563\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58563\",\"name\":\"HealZen's BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-02T06:16:49+00:00\",\"description\":\"Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has received clinical approval from China's National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58563#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58563\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58563#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HealZen&#8217;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HealZen's BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has received clinical approval from China's National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58563","og_locale":"en_US","og_type":"article","og_title":"HealZen's BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline","og_description":"Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has received clinical approval from China's National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.","og_url":"https:\/\/flcube.com\/?p=58563","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T06:16:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58563#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58563"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HealZen&#8217;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline","datePublished":"2026-03-02T06:16:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58563"},"wordCount":427,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HealZen Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58563#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58563","url":"https:\/\/flcube.com\/?p=58563","name":"HealZen's BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-02T06:16:49+00:00","description":"Hangzhou HealZen Therapeutics Co., Ltd. announced that its self\u2011developed Category\u202f1 innovative drug, HZ\u2011A\u2011018 capsules, has received clinical approval from China's National Medical Products Administration (NMPA) to conduct a Phase II trial for the monotherapy of chronic spontaneous urticaria (CSU). The highly selective BTK inhibitor adds a dermatologic autoimmune indication to its expanding pipeline spanning oncology and multiple immunology targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58563#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58563"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58563#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HealZen&#8217;s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II \u2013 Expands Autoimmune Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58563"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58563\/revisions"}],"predecessor-version":[{"id":58565,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58563\/revisions\/58565"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}